Please login to the form below

Not currently logged in
Email:
Password:

CAR-T

This page shows the latest CAR-T news and features for those working in and with pharma, biotech and healthcare.

MaxCyte gets green light for solid tumour cell therapy

MaxCyte gets green light for solid tumour cell therapy

The current generation of CAR-T therapies – namely Novartis’Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) – use engineered T cells harvested from blood, which have to be expanded in ... Difficulties in getting to

Latest news

More from news
Approximately 26 fully matching, plus 66 partially matching documents found.

Latest Intelligence

  • No incentive for a cure No incentive for a cure

    These include Kymriah, the pioneering CAR-T cell therapy from Novartis, which demonstrated a remarkable 83% remission rate in children and young adults with B-cell precursor acute lymphoblastic leukaemia. ... We won’t know for many years if the

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    But we don’t need any more pilots; the concept has been proven.”. ... CAR-T cell therapy for children with B-cell ALL.

  • The rise of real-world evidence The rise of real-world evidence

    Novartis secured such an outcome-based model for its CAR-T therapy Kymriah.

  • Deal Watch January 2018

    Impact Biomedicines for a potential $7bn in early January and then it scooped up the remaining 90% of its CAR-T and TCR technology partner Juno Therapeutics for $9bn. ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics portfolio incl JCAR017

  • The good, the bad and the ugly The good, the bad and the ugly

    The company hopes its $12bn acquisition of Kite Pharma (August 2017) will help it steal a march on the lucrative CAR-T market through its treatment for advanced lymphoma. ... It will also be interesting to see how gene therapies and cell-based therapies,

More from intelligence
Approximately 0 fully matching, plus 32 partially matching documents found.

Latest appointments

  • Celgene boosts CAR-T stake again with Bluebird Bio deal Celgene boosts CAR-T stake again with Bluebird Bio deal

    CAR-T uses modified versions of a patient's own white blood cells to attack malignant cells. ... It could also receive additional, undisclosed milestones if the CAR-T is developed for other indications.

  • Rainer Boehm and Hervé Hoppenot join Cellectics board Rainer Boehm and Hervé Hoppenot join Cellectics board

    Through its work in developing CAR-T immunotherapies, Cellectis has an opportunity to make a significant contribution to the treatment of cancer. ... Rainer’s experience in drug commercialisation will be invaluable as we work to develop the next

  • Celyad appoints Dr David Gilham as R&D vice president Celyad appoints Dr David Gilham as R&D vice president

    Dr Gilham brings extensive experience in the field of CAR-T cells, with his research activity focused on engineering T-cells for cancer therapies and pre-clinical study development. ... Engineering immune system T-cells to attack and eradicate cancer is

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Training the next generation of biotech leaders

    In this year alone, the FDA has taken the groundbreaking step of approving two CAR-T therapies. ... In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’ s Yescarta in October.

  • Addressing the biggest challenges for rare disease communities

    It is common that primary care physicians either do not recognise specific symptoms or don’ t make the link between common symptoms and a rare disease. ... And just last year, we saw landmark breakthroughs in advanced genetic therapies, such as viral

  • How do you define a biotech company?

    This approach is particularly apparent in some of the recent examples of technology pioneered by biotech organisations, such as CAR-T technology (Novartis, Juno and Kite Pharma) and RNAi (Alnylam) where  ... However, we can’ t say that this is a trait

  • Addressing the biggest challenges for rare disease communities

    It is common that primary care physicians either do not recognise specific symptoms or don’ t make the link between common symptoms and a rare disease. ... And just last year, we saw landmark breakthroughs in advanced genetic therapies, such as viral

  • Innovation in pharma: the highs and lows of the current healthcare economy

    Also in cancers: chimeric antigen receptor T cell (CAR-T) therapy, a type of cancer immunology that could dismiss chemotherapy in some cancers, is now licensed in the US.

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics